Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions
ABSTRACT Furmonertinib demonstrated potent efficacy as a newly developed tyrosine kinase inhibitor for the treatment of patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer. In vitro research showed that furmonertinib is metabolized to its active metabol...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.70052 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849701453055131648 |
|---|---|
| author | Yali Wu Helena Leonie Hanae Loer Yifan Zhang Dafang Zhong Yong Jiang Jie Hu Uwe Fuhr Thorsten Lehr Xingxing Diao |
| author_facet | Yali Wu Helena Leonie Hanae Loer Yifan Zhang Dafang Zhong Yong Jiang Jie Hu Uwe Fuhr Thorsten Lehr Xingxing Diao |
| author_sort | Yali Wu |
| collection | DOAJ |
| description | ABSTRACT Furmonertinib demonstrated potent efficacy as a newly developed tyrosine kinase inhibitor for the treatment of patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer. In vitro research showed that furmonertinib is metabolized to its active metabolite AST5902 via the cytochrome P450 (CYP) enzyme CYP3A4. Furmonertinib is a strong CYP3A4 inducer, while the metabolite is a weaker CYP3A4 inducer. In clinical studies, nonlinear pharmacokinetics were observed during chronic dosing. The apparent clearance showed time‐ and dose‐dependent increases. In this evaluation, a combination of in vitro data using radiolabeled compounds, clinical pharmacokinetic data, and drug–drug interaction (DDI) data of furmonertinib in oncology patients and/or in healthy subjects was used to develop a physiologically based pharmacokinetic (PBPK) model. The model was built in PK‐Sim Version 11 using a total of 44 concentration‐time profiles of furmonertinib and its metabolite AST5902. Suitability of the predictive model performance was demonstrated by both goodness‐of‐fit plots and statistical evaluation. The model predicted the observed monotherapy concentration profiles of furmonertinib well, with 32/32 predicted AUClast (area under the curve until the last concentration measurement) values and 32/32 maximum plasma concentration (Cmax) ratios being within twofold of the respective observed values. In addition, 8/8 predicted DDI AUClast and Cmax ratios with furmonertinib as a victim of CYP3A4 inhibition or induction were within twofold of their respective observed values. Potential applications of the final model include the prediction of DDIs for chronic administration of CYP3A4 perpetrators along with furmonertinib, considering auto‐induction of furmonertinib and its metabolite AST5902. |
| format | Article |
| id | doaj-art-9e9d441d52894e79b9950b8dd9705f73 |
| institution | DOAJ |
| issn | 2163-8306 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | CPT: Pharmacometrics & Systems Pharmacology |
| spelling | doaj-art-9e9d441d52894e79b9950b8dd9705f732025-08-20T03:17:55ZengWileyCPT: Pharmacometrics & Systems Pharmacology2163-83062025-07-011471273128410.1002/psp4.70052Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction PredictionsYali Wu0Helena Leonie Hanae Loer1Yifan Zhang2Dafang Zhong3Yong Jiang4Jie Hu5Uwe Fuhr6Thorsten Lehr7Xingxing Diao8Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaClinical Pharmacy Saarland University Saarbrücken GermanyShanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaShanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaShanghai Allist Pharmaceuticals Co., Ltd Shanghai ChinaShanghai Allist Pharmaceuticals Co., Ltd Shanghai ChinaClinical Pharmacology, Department I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne University of Cologne Cologne GermanyClinical Pharmacy Saarland University Saarbrücken GermanyShanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai ChinaABSTRACT Furmonertinib demonstrated potent efficacy as a newly developed tyrosine kinase inhibitor for the treatment of patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer. In vitro research showed that furmonertinib is metabolized to its active metabolite AST5902 via the cytochrome P450 (CYP) enzyme CYP3A4. Furmonertinib is a strong CYP3A4 inducer, while the metabolite is a weaker CYP3A4 inducer. In clinical studies, nonlinear pharmacokinetics were observed during chronic dosing. The apparent clearance showed time‐ and dose‐dependent increases. In this evaluation, a combination of in vitro data using radiolabeled compounds, clinical pharmacokinetic data, and drug–drug interaction (DDI) data of furmonertinib in oncology patients and/or in healthy subjects was used to develop a physiologically based pharmacokinetic (PBPK) model. The model was built in PK‐Sim Version 11 using a total of 44 concentration‐time profiles of furmonertinib and its metabolite AST5902. Suitability of the predictive model performance was demonstrated by both goodness‐of‐fit plots and statistical evaluation. The model predicted the observed monotherapy concentration profiles of furmonertinib well, with 32/32 predicted AUClast (area under the curve until the last concentration measurement) values and 32/32 maximum plasma concentration (Cmax) ratios being within twofold of the respective observed values. In addition, 8/8 predicted DDI AUClast and Cmax ratios with furmonertinib as a victim of CYP3A4 inhibition or induction were within twofold of their respective observed values. Potential applications of the final model include the prediction of DDIs for chronic administration of CYP3A4 perpetrators along with furmonertinib, considering auto‐induction of furmonertinib and its metabolite AST5902.https://doi.org/10.1002/psp4.70052 |
| spellingShingle | Yali Wu Helena Leonie Hanae Loer Yifan Zhang Dafang Zhong Yong Jiang Jie Hu Uwe Fuhr Thorsten Lehr Xingxing Diao Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions CPT: Pharmacometrics & Systems Pharmacology |
| title | Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions |
| title_full | Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions |
| title_fullStr | Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions |
| title_full_unstemmed | Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions |
| title_short | Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions |
| title_sort | development and verification of a physiologically based pharmacokinetic model of furmonertinib and its main metabolite for drug drug interaction predictions |
| url | https://doi.org/10.1002/psp4.70052 |
| work_keys_str_mv | AT yaliwu developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions AT helenaleoniehanaeloer developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions AT yifanzhang developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions AT dafangzhong developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions AT yongjiang developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions AT jiehu developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions AT uwefuhr developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions AT thorstenlehr developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions AT xingxingdiao developmentandverificationofaphysiologicallybasedpharmacokineticmodeloffurmonertinibanditsmainmetabolitefordrugdruginteractionpredictions |